Skip to main content
HANALL BIOPHARMA CO.,LTD logo

HANALL BIOPHARMA CO.,LTD — Investor Relations & Filings

Ticker · 009420 ISIN · KR7009420001 KO Manufacturing
Open in API
Filings indexed 336 across all filing types
Latest filing 2025-06-02 Transaction in Own Shar…
Country KR South Korea
Listing KO 009420

About HANALL BIOPHARMA CO.,LTD

http://www.hanallbiopharma.com/

HanAll Biopharma is a global biopharmaceutical company focused on developing innovative, first-in-class therapies for patients with unmet medical needs. The company's research and development efforts are centered on immunology, ophthalmology, and immuno-oncology, with a specialization in antibody-based therapeutics. Its pipeline includes novel treatments for autoimmune diseases and dry eye disease. The company's mission is to pioneer cutting-edge medicines that address incurable and immune-associated conditions. Alongside its innovative pipeline, HanAll Biopharma also operates a portfolio of pharmaceutical products in therapeutic areas including endocrine, circulatory, and urologic diseases.

Recent filings

Filing Released Lang Actions
자기주식처분결과보고서
Transaction in Own Shares Classification · 100% confidence The document is a '자기주식처분결과보고서' (Report on the Results of Disposal of Treasury Shares) filed with the Financial Supervisory Service (금융감독원). It details the specific number of shares disposed of, the disposal price, and the purpose (employee stock options/incentives). This falls directly under the category of a company reporting the sale or disposal of its own shares.
2025-06-02 Korean
기업지배구조보고서공시
Governance Information Classification · 100% confidence The document is a 'Corporate Governance Report' (기업지배구조보고서) for the company HanAll Biopharma. It details the company's governance structure, board composition, shareholder rights, and compliance with governance indicators. This type of report is a mandatory regulatory filing in South Korea, typically submitted annually to the Korea Exchange (KRX). It is not an Annual Report (10-K), nor is it a simple announcement (RPA), but rather a specific governance disclosure document. Within the provided categories, 'Governance Information' (CGR) is the most accurate classification.
2025-05-30 Korean
분기보고서 (2025.03)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for HanAll Biopharma Co., Ltd. for the period ending March 31, 2025. It contains detailed financial statements, management discussion and analysis, and corporate governance information, which aligns with the definition of an Interim/Quarterly Report (IR). Q1 2025
2025-05-15 Korean
연결재무제표기준영업(잠정)실적(공정공시)
Earnings Release Classification · 100% confidence The document is a formal announcement of preliminary financial results (Earnings Release) for the first quarter of 2025. It contains key financial metrics such as revenue, operating profit, and net income, presented in a table format typical of a Korean stock exchange (KRX) 'Fair Disclosure' (공정공시) filing. Since it provides the initial highlights of quarterly performance rather than a full report or a mere announcement of a report's publication, it is classified as an Earnings Release. Q1 2025
2025-04-30 Korean
주요사항보고서(자기주식처분결정)
Transaction in Own Shares Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) from HanAll Biopharma regarding the 'Decision to Dispose of Treasury Shares' (자기주식 처분 결정). This filing details the company's plan to dispose of its own shares due to employee stock option exercises. According to the provided definitions, a report of a company buying back or selling its own shares (share repurchase/issuance) is classified as 'Transaction in Own Shares' (POS).
2025-04-30 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service. It details the share ownership and changes in holdings (specifically stock option exercises) by an executive (Park Seung-kook) of HanAll Biopharma. This type of filing is classified as a Director's Dealing (DIRS) as it reports personal share transactions by company executives.
2025-04-30 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.